Olema Pharmaceuticals

NSQ:OLMA · US68062P1066

BiotechnologySmall

360° View

Value45

Price/Sales21

Price/Earnings42

Price/Book54

Dividend Yield—

Growth42

Revenue Growth—

Profit Growth33

Capital Growth18

TSR 52w78

Safety41

Leverage85

Liquidity25

Refinancing29

Combined43

Sentiment35

Analyst Opinions30

Pro Holdings83

Opinion Changes50

Market Pulse33

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2006

Employees143

Websiteolema.com

ISINUS68062P1066

Last UpdateApr 2, 2026

Index & Theme

Women's HealthOncologyBiopharmaBiotechnologyHealth CareMedicalPharmaceutical

Description

Olema Pharmaceuticals, Inc. (Olema), a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. The company is advancing its pipeline o…

Analysis

Olema Pharmaceuticals's 360° View rank of 28 places it below its peer average — better than 28% of its true peers.

It's growing slowly (42) and on the expensive side (45). On safety it is carrying more balance-sheet risk (41), and the market shows muted sentiment (35). Taken together, its Combined rank of 43 reads as below its peer average.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Olema Pharmaceuticals with its peers

Celcuity

NAQ:CELC

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Oncolytics Biotech

NAQ:ONCY

—

CountryCanada

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Oric Pharmaceuticals

NSQ:ORIC

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Greenwich Lifesciences

NAQ:GLSI

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Nuvalent

NSQ:NUVL

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Syndax Pharmaceuticals

NSQ:SNDX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →